Palatin Technologies (PTN) investor relations material

Company overview and leadership

• Focuses on developing therapeutics targeting the melanocortin system, especially MC4R agonists for syndromic and genetic obesity.

• Demonstrated expertise from discovery to FDA approval, including VyleesiⓇ for female sexual dysfunction.

• Leadership team has extensive experience in drug development, finance, operations, and business development.

Development programs and pipeline

• Advancing next-generation MC4R selective agonists for rare neuroendocrine diseases: hypothalamic obesity (HO), Prader-Willi syndrome (PWS), and Bardet-Biedl syndrome (BBS).

• Pipeline includes once-weekly injectable peptides and daily oral small molecules, both in preclinical and early clinical stages.

• IND filings for peptide and oral programs targeted for late 2026 and early 2027, with Phase 1 and 2/3 studies planned through 2028.

Scientific and clinical highlights

• MC4R pathway is validated for obesity and energy management; rare diseases HO, PWS, and BBS have high unmet needs.

• Next-generation MC4R agonists show improved selectivity, potency, and reduced off-target effects, minimizing hyperpigmentation and cardiovascular risks.

• Preclinical and early clinical data demonstrate significant weight loss and favorable safety profiles.